Canada Markets closed

Arcturus Therapeutics Holdings Inc. (ARCT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
20.59+0.59 (+2.95%)
At close: 04:00PM EST
20.26 -0.33 (-1.60%)
After hours: 05:41PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close20.00
Open19.95
Bid20.25 x 1300
Ask22.80 x 800
Day's Range19.95 - 21.35
52 Week Range11.70 - 31.41
Volume270,220
Avg. Volume574,736
Market Cap542.763M
Beta (5Y Monthly)2.57
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

    SAN DIEGO, December 19, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time.

  • Business Wire

    Arcturus Appoints John Markels, Ph.D. to its Board of Directors

    SAN DIEGO, December 13, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that is has appointed John Markels, Ph.D., an accomplished pharmaceutical executive with over 35 years of industry experience, to its Board of Directors. As part of this role, Dr. Ma

  • Business Wire

    Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress

    SAN DIEGO, November 09, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", "Arcturus Therapeutics", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the third quarter ended September 30, 2022, and provided corporate updates.